Verve Therapeutics reported progress in its pipeline development, including the Heart-2 Phase 1b clinical trial of VERVE-102 and the Pulse-1 Phase 1b clinical trial of VERVE-201. The company's cash, cash equivalents, and marketable securities totaled $524.3 million, expected to fund operations into mid-2027. Frederick T. Fiedorek, M.D., will retire from his position as Chief Medical Officer, effective February 28, 2025.

Verve Therapeutics announced pipeline updates and financial results for the quarter ended September 30, 2024. Key highlights include progress in the Heart-2 Phase 1b clinical trial of VERVE-102, the first participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201, and a cash position of $539.9 million expected to fund operations through 2026.

Verve Therapeutics reported a net loss of $49.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $575.9 million, expected to fund operations into late 2026. The Heart-2 Phase 1b clinical trial of VERVE-102 continues to progress, and the Phase 1b clinical trial for VERVE-201 is on track for the second half of 2024.

Verve Therapeutics reported a net loss of $48.7 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $606.4 million, expected to fund operations into late 2026. They also achieved the first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)).

Verve Therapeutics reported a net loss of $48.4 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $624.0 million as of December 31, 2023, expected to fund operations into late 2026. The company made progress with its clinical programs, including VERVE-101, VERVE-102, and VERVE-201, and anticipates having three in vivo gene editing programs in the clinic in 2024.

Verve Therapeutics reported a net loss of $45.8 million for the third quarter of 2023 and ended the quarter with $485.2 million in cash, cash equivalents, and marketable securities. The company anticipates its cash runway will extend into 2026. They also announced the FDA cleared the IND application for VERVE-101, and interim data from the heart-1 Phase 1b clinical trial of VERVE-101 will be presented at AHA.

Verve Therapeutics reported a net loss of $54.0 million for the second quarter of 2023. The company's cash position remains strong with $462.5 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026. The company is advancing its pipeline, including VERVE-101, VERVE-102, and VERVE-201, and progressing in its collaboration with Lilly.

Verve Therapeutics reported pipeline progress and financial results for the first quarter of 2023. The company's lead program, VERVE-101, is being evaluated in the heart-1 clinical trial, and two additional programs are expected to advance into the clinic next year. Verve ended the quarter with $508.7 million in cash, which is expected to fund operations into the second half of 2025.

Verve Therapeutics reported a net loss of $41.1 million for the fourth quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $554.8 million as of December 31, 2022, which is expected to fund operations into the second half of 2025.

Verve Therapeutics reported its Q3 2022 financial results, with a net loss of $45.2 million. The FDA placed a hold on its IND application for VERVE-101. The company's cash, cash equivalents and marketable securities were $550.7 million as of September 30, 2022, which is expected to fund operations into the second half of 2025.

Verve Therapeutics reported a net loss of $40.9 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $293.6 million as of June 30, 2022, which, combined with proceeds from the Vertex collaboration and follow-on offering, is expected to fund operations into the second half of 2025. Patient dosing commenced for VERVE-101, and a lead development candidate, VERVE-201, was nominated.

Verve Therapeutics announced the clearance of its first VERVE-101 clinical trial application and outlined its global clinical development strategy. The company's cash, cash equivalents, and marketable securities totaled $323.3 million, providing a cash runway into 2024. Net loss for the quarter was $30.2 million, or $0.62 per share.

Verve Therapeutics reported a net loss of $31.3 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $360.4 million as of December 31, 2021, expected to fund operations into 2024. The company is advancing its VERVE-101 program and planning IND-enabling studies for its ANGPTL3 program.

Verve Therapeutics reported a net loss of $22.7 million for the third quarter of 2021, with cash, cash equivalents, and marketable securities totaling $389.2 million as of September 30, 2021. The company's pipeline progress includes VERVE-101 clinical initiation on track for 2022 and preclinical data highlighting liver-targeted delivery with proprietary GalNAc-LNP Technology.

Verve Therapeutics reported a net loss of $53.0 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities were $417.6 million as of June 30, 2021, which includes net proceeds from Verve’s successful initial public offering.